Addendum:  OnCore License

At the request of NASDAQ OMX Stockholm, the Company provides the following information regarding the license agreement referred to in the press release dated September 9, 2014.

Report from AGM

NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) today, 9 May 2014. A summary of the resolutions follows. All decisions received the required majorities.